What is Intrapace?
Intrapace is a pioneering medical device and therapeutic firm dedicated to addressing the unmet needs of patients suffering from chronic gastrointestinal disorders, specifically Crohn's disease and ulcerative colitis. The company's core competency lies in the development of sophisticated diagnostic and treatment platforms. These include proprietary innovations for inflammation and ischemia sensing, as well as sensor-based closed-loop localized drug delivery systems. By integrating surgical marking technologies with real-time physiological monitoring, Intrapace is effectively bridging the gap between diagnostic precision and therapeutic intervention, positioning itself as a critical player in the evolving landscape of IBD management.
How much funding has Intrapace raised?
Intrapace has raised a total of $129.3M across 5 funding rounds:
Unspecified
$116.9M
Unspecified
$6.2M
Multiple Rounds
$6.2M
Unspecified (2010): $116.9M, investors not publicly disclosed
Unspecified (2012): $6.2M, investors not publicly disclosed
Debt (2013): $624K, investors not publicly disclosed
Unspecified (2013): $2.2M, investors not publicly disclosed
Unspecified (2013): $3.3M, investors not publicly disclosed
Key Investors in Intrapace
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Intrapace?
With the recent influx of capital, Intrapace is well-positioned to accelerate its clinical validation programs and scale its manufacturing capabilities. The strategic focus will likely shift toward securing regulatory milestones and expanding the commercial footprint of its sensor-based delivery systems. As the firm transitions into a more mature operational phase, the emphasis will remain on demonstrating long-term clinical efficacy and cost-effectiveness to healthcare providers. This growth phase is essential for establishing the company as a standard-bearer in the next generation of gastrointestinal care, potentially attracting further institutional interest as it moves toward broader market adoption.
See full Intrapace company page
